GlassScriptPhysician profile
James D Williams
NPI 1467404657
$3,542.56
in general payments reported to CMS, 2019-2025
22 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $225 · 2021: $195 · 2022: $193 · 2023: $424 · 2024: $611 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Education: $42.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.60 |
| Education | $42.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $933.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $568.74 | 2023-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $411.62 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $294.48 | 2019-2025 | Xolair |
| Optinose US, INC. | $226.93 | 2019-2025 | |
| Genzyme Corporation | $157.06 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $131.35 | 2024-2025 | Voquezna |
| Csl Behring | $130.42 | 2024-2025 | Andembry, Haegarda |
| Amgen INC. | $119.49 | 2023-2025 | Tezspire |
| Stryker Corporation | $95.09 | 2023-2025 | Scopis Ent, Xpress Loprofile |
| Takeda Pharmaceuticals U.S.A., INC. | $71.77 | 2024-2025 | Elaprase, Hyqvia, Takhzyro |
| Smith+Nephew, INC. | $69.42 | 2025 | Lens 4k, N/A |
| Pharming Healthcare, INC. | $68.87 | 2023-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $61.29 | 2024-2025 | |
| Aerin Medical INC. | $47.97 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $42.99 | 2023 | |
| Cycle Pharmaceuticals INC | $31.56 | 2024 | Sajazir |
| Teleflex LLC | $19.11 | 2023 | Urolift |
| Neurent Medical Limited | $18.00 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Acclarent, INC | $15.04 | 2019 | |
| Kedrion Biopharma, INC. | $14.80 | 2025 | Kedrab, Koate, Gammaked |
| Hikma Pharmaceuticals USA | $13.36 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.